96 related articles for article (PubMed ID: 2940961)
1. Antimigraine drug interactions with 5-hydroxytryptamine1A receptors.
Hiner BC; Roth HL; Peroutka SJ
Ann Neurol; 1986 May; 19(5):511-3. PubMed ID: 2940961
[TBL] [Abstract][Full Text] [Related]
2. Antimigraine drug interactions with serotonin receptor subtypes in human brain.
Peroutka SJ
Ann Neurol; 1988 May; 23(5):500-4. PubMed ID: 2898916
[TBL] [Abstract][Full Text] [Related]
3. Serotonin depletion unmasks serotonergic component of [3H]dihydroalprenolol binding in rat brain.
Stockmeier CA; Kellar KJ
Mol Pharmacol; 1989 Dec; 36(6):903-11. PubMed ID: 2557537
[TBL] [Abstract][Full Text] [Related]
4. Canine basilar artery contractions mediated by 5-hydroxytryptamine1A receptors.
Peroutka SJ; Huang S; Allen GS
J Pharmacol Exp Ther; 1986 Jun; 237(3):901-6. PubMed ID: 2940360
[TBL] [Abstract][Full Text] [Related]
5. New methoxy-chroman derivatives, 4[N-(5-methoxy-chroman-3-yl)N- propylamino]butyl-8-azaspiro-(4,5)-decane-7,9-dione [(+/-)-S 20244] and its enantiomers, (+)-S 20499 and (-)-S 20500, with potent agonist properties at central 5-hydroxytryptamine1A receptors.
Kidd EJ; Haj-Dahmane S; Jolas T; Lanfumey L; Fattaccini CM; Guardiola-Lemaitre B; Gozlan H; Hamon M
J Pharmacol Exp Ther; 1993 Feb; 264(2):863-72. PubMed ID: 8094756
[TBL] [Abstract][Full Text] [Related]
6. Selective irreversible blockade of 5-hydroxytryptamine1A and 5-hydroxytryptamine1C receptor binding sites in the rat brain by 8-MeO-2'-chloro-PAT: a quantitative autoradiographic study.
Radja F; Daval G; Emerit MB; Gallissot MC; Hamon M; Vergé D
Neuroscience; 1989; 31(3):723-33. PubMed ID: 2531850
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist.
De Vry J; Schohe-Loop R; Heine HG; Greuel JM; Mauler F; Schmidt B; Sommermeyer H; Glaser T
J Pharmacol Exp Ther; 1998 Mar; 284(3):1082-94. PubMed ID: 9495870
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of four migraine prophylactic drugs on an isolated extracranial artery.
Fozard JR
Eur J Pharmacol; 1976 Mar; 36(1):127-139. PubMed ID: 1261590
[TBL] [Abstract][Full Text] [Related]
9. Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors.
Peroutka SJ
Biol Psychiatry; 1985 Sep; 20(9):971-9. PubMed ID: 2862927
[TBL] [Abstract][Full Text] [Related]
10. Receptors for 5-hydroxytryptamine and noradrenaline in rabbit isolated ear artery and aorta.
Apperley E; Humphrey PP; Levy GP
Br J Pharmacol; 1976 Oct; 58(2):211-21. PubMed ID: 184872
[TBL] [Abstract][Full Text] [Related]
11. The role of the central serotonergic system in pilocarpine-induced seizures: receptor mechanisms.
Janusz W; Kleinrok Z
Neurosci Res; 1989 Nov; 7(2):144-53. PubMed ID: 2533336
[TBL] [Abstract][Full Text] [Related]
12. 125I-Bolton-Hunter-8-methoxy-2-[N-propyl-N-propylamino]tetralin as a new selective radioligand of 5-HT1A sites in the rat brain. In vitro binding and autoradiographic studies.
Gozlan H; Ponchant M; Daval G; Verge D; Menard F; Vanhove A; Beaucourt JP; Hamon M
J Pharmacol Exp Ther; 1988 Feb; 244(2):751-9. PubMed ID: 2964524
[TBL] [Abstract][Full Text] [Related]
13. Potential vascular alpha1-adrenoceptor blocking properties of an array of 5-HT receptor ligands in the rat.
Centurión D; Mehotra S; Sánchez-López A; Gupta S; MaassenVanDenBrink A; Villalón CM
Eur J Pharmacol; 2006 Mar; 535(1-3):234-42. PubMed ID: 16545797
[TBL] [Abstract][Full Text] [Related]
14. Tertatolol, a new beta-blocker, is a serotonin (5-hydroxytryptamine1A) receptor antagonist in rat brain.
Prisco S; Cagnotto A; Talone D; De Blasi A; Mennini T; Esposito E
J Pharmacol Exp Ther; 1993 May; 265(2):739-44. PubMed ID: 8496820
[TBL] [Abstract][Full Text] [Related]
15. Differential interactions of "prosexual" drugs with 5-hydroxytryptamine1A and alpha 2-adrenergic receptors.
Kwong LL; Smith ER; Davidson JM; Peroutka SJ
Behav Neurosci; 1986 Oct; 100(5):664-8. PubMed ID: 2877677
[TBL] [Abstract][Full Text] [Related]
16. 6-substituted tricyclic partial ergoline compounds are selective and potent 5-hydroxytryptamine1A receptor agents.
Slaughter JL; Harrington MA; Peroutka SJ
Life Sci; 1990; 47(15):1331-7. PubMed ID: 2172684
[TBL] [Abstract][Full Text] [Related]
17. Modulation of postdecapitation convulsions in rats by alpha-adrenergic and 5-hydroxytryptamine1A agents.
Peroutka SJ; Gonzales DA; Shapiro M
Exp Neurol; 1987 May; 96(2):344-51. PubMed ID: 2883018
[TBL] [Abstract][Full Text] [Related]
18. Studies on the 5-HT receptor in vascular smooth muscle.
Müller-Schweinitzer E
Res Clin Stud Headache; 1978; 6():6-12. PubMed ID: 725257
[TBL] [Abstract][Full Text] [Related]
19. The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299.
Johansson L; Sohn D; Thorberg SO; Jackson DM; Kelder D; Larsson LG; Rényi L; Ross SB; Wallsten C; Eriksson H; Hu PS; Jerning E; Mohell N; Westlind-Danielsson A
J Pharmacol Exp Ther; 1997 Oct; 283(1):216-25. PubMed ID: 9336327
[TBL] [Abstract][Full Text] [Related]
20. Potency of 5-hydroxytryptamine1a agonists to inhibit adenylyl cyclase activity is a function of affinity for the "low-affinity" state of [3H]8-hydroxy-N,N-dipropylaminotetralin ([3H]8-OH-DPAT) binding.
Chamberlain J; Offord SJ; Wolfe BB; Tyau LS; Wang HL; Frazer A
J Pharmacol Exp Ther; 1993 Aug; 266(2):618-25. PubMed ID: 8355195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
